Fig. 5.From: Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma18F-FDG PET/CT images of the patient six months after initiation of therapy with erlotinib. MIP image (4a) transaxial CT images (4b–4e) and fused PET/C images (4f–4i) show no significant interval change in size and metabolic activity of the left axillary lymph node, anterior abdominal wall lesion and omental/mesenteric deposits and lesion near left ischial tuberosity (arrows), suggestive of stable diseaseBack to article page